SuperworthP3 Health Partners PIII
- Market cap
- $30.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.5B
- +3% on a year ago
- Net margin
- −6.6%
- Free cash flow yield
- n/m
- not a meaningful number
P3 Health Partners trades at 0.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.5B over the last twelve months, up 3% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $288.4M+16% | $346.9M+34% | $388.5M+29% | $379.2M+15% | $362.1M+26% | $370.7M+7% | $373.2M−4% | $355.8M−6% | $345.3M−5% | $384.8M+4% | $386.4M+4% | $386.4M+9% | |
| SG&A | $33.7M−14% | $25.2M−39% | $27.7M−28% | $27M−4% | $27.4M−19% | $31.8M+27% | $25.2M−9% | $23.4M−13% | $22.4M−18% | $36.2M+14% | $25.8M+2% | $32.4M+38% |
| −$33.8M−44% | −$64.3M−88% | −$43.8M−10% | −$31.3M+49% | −$107M+216% | −$138.5M+116% | −$38.1M−13% | −$34.1M+9% | −$44.2M−59% | −$153.9M+11% | $8.2M | $41.2M | |
| Interest expense | $4M+35% | $4M+36% | $4.3M+4% | $5.4M+41% | $5.6M+41% | $6.8M+69% | $8.7M+105% | $10.1M+87% | $20.5M+264% | $15.6M+129% | $16.8M+92% | $7.9M−23% |
| Pre-tax income | −$36.9M−44% | −$67.3M−87% | −$47.5M−9% | −$27.8M+2% | −$106.5M+189% | −$124.2M+84% | −$43.2M−9% | −$41.7M+50% | −$69.5M−35% | −$166.8M+34% | −$8M−82% | $16.9M |
| $412K | $1.8M−5% | $2.1M+615% | $968K+328% | −$3.6M | $5M+180% | $1.1M−48% | $2M+105% | $11K | −$1M | −$11M | $1.3M−36% | |
| Net income | −$13.3M+19% | −$25.5M−73% | −$18.7M+103% | −$12M+23% | −$46.5M+250% | −$58.6M+130% | −$20.5M+10% | −$20.4M+69% | −$31.6M−32% | −$75.5M+29% | $1.2M | $7.4M |
| −$0.12−56% | −$0.22 | −$7.86+3473% | −$7.37+8089% | −$15.70+12983% | −$18.01+8086% | −$6.28−20% | −$6.23−16% | −$9.67−38% | −$23.02+28% | $0.32 | −$0.63−90% | |
| 312.7M+29% | 115.3M | 2.4M−94% | 2.8M−97% | 3.3M−99% | 3.3M−97% | 3.3M+37% | 3.3M+16% | 3.3M−1% | 3.3M+1% | 8.4M+158% | 3.4M+3% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest P3 Health Partners' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PIIIP3 Health Partners | $30.1M | n/m | n/a | 0.0× | +3% | −6.6% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on P3 Health Partners
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 496Healthcare stocks with the lowest price to sales ratio
- #1of 45Hospital and care facility stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .